Yang Wang

Yang Wang

Auto-generated profile, based on publicly available information

Yang Wang

Institute of Immunotherapy, Fujian Medical University, Fuzhou, Fujian, 350102, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2020 in Journal of Immunotherapy
Verified
Journal Article
Closed access
YWYang Wang
Yang Wang
HLHui Li
Hui Li
WXWei Xu
Wei Xu
MPMingzhu Pan
Mingzhu Pan
CQChun Qiao
Chun Qiao
JZJuan Zhang
Juan Zhang
B-cell maturation antigen (BCMA) is a highly plasma cell-selective protein expressed on malignant plasma cells of patients with multiple myeloma (MM), and it is a defined therapeutic target. Major histocompatibility complex class I-related chain A (MICA) is frequently expressed in lymphoproliferative malignancies including MM. MICA activates natural killer (NK) cells and costimulates T cells by interaction with its immunoreceptor NK cell receptor G2D (NKG2D). Nonetheless, during full-blown MM, tumor cells promote efficient MICA shedding, which evokes NKG2D internalization and immune suppression. To enhance the directional killing efficacy of immune cells against myeloma cells, we constructed a novel bispecific antibody 2A9-MICA and explored its potential antimyeloma activity against MM. 2A9-MICA consists of human MICA extracellular region and a single–chain antibody fragment (scFv) that targets BCMA generated by phage display technology. In vitro, 2A9-MICA activated NK cell-mediated cytotoxicity and induced NK cells to kill BCMA–positive human myeloma cells. Moreover, in BCMA-positive, MM-bearing nude mice, 2A9-MICA specifically targeted tumor tissue, where it effectively recruited immune cells and inhibited tumor tissue growth showed superior antitumor activity. Taken together, bispecific antibody 2A9-MICA provides a new approach for MM-targeting immunotherapy and has attractive potential for clinical applications.

25 March 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
WLWenning Lan
Wenning Lan
YWYang Wang
Yang Wang
Zixiong ZhouZixiong Zhou
Zixiong Zhou
XSXia Sun
Xia Sun
YZYun Zhang
Yun Zhang
FANGRONG ZHANGFANGRONG ZHANG
FANGRONG ZHANG
Hepatitis B virus (HBV) infection is a worldwide health burden. Metabolomics analysis has revealed HBV-induced metabolism dysregulation in liver tissues and hepatocytes. However, as an infectious disease, the tissue-specific landscape of metabolic profiles of HBV infection remains unclear. To fill this gap, we applied untargeted nuclear magnetic resonance (NMR) metabolomic analysis of the heart, liver, spleen, lung, kidney, pancreas, and intestine (duodenum, jejunum, ileum) in HBV-transgenic mice and their wild-type littermates. Strikingly, we found systemic metabolic alterations induced by HBV in liver and extrahepatic organs. Significant changes in metabolites have been observed in most tissues of HBV-transgenic mice, except for ileum. The metabolic changes may provide novel therapeutic targets for the treatment of HBV infection. Moreover, tissue-specific metabolic profiles could speed up the study of HBV induced systemic metabolic reprogramming, which could help follow the progression of HBV infection and explain the underlying pathogenesis.

8 January 2024 in Cancer Letters
Verified
Journal Article
Closed access
LCLing Chen
Ling Chen
PHPing Hou
Ping Hou
YZYu-Lian Zou
Yu-Lian Zou
YWYang Wang
Yang Wang
LZLin-Lin Zhou
Lin-Lin Zhou
LLLin Lin
Lin Lin